These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14504207)

  • 1. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
    Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
    Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
    Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
    Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
    Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic association in
    Bellah SF; Salam MA; Billah SMS; Karim MR
    Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
    Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
    Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
    Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
    Garsa AA; McLeod HL; Marsh S
    BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
    Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
    Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
    Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
    Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
    Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
    Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
    Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
    BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
    Islam MS; Mostofa AG; Ahmed MU; Bin Sayeed MS; Hassan MR; Hasnat A
    Tumour Biol; 2014 Feb; 35(2):1671-8. PubMed ID: 24085358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Keshava C; McCanlies EC; Weston A
    Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
    Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
    Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the minor cytochrome P450 3A isoforms.
    Daly AK
    Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.